Spruce Biosciences, Inc.
SPRBD
$8.20
-$0.30-3.53%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 2.91M | 4.91M | 7.10M | 9.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 2.91M | 4.91M | 7.10M | 9.57M |
| Cost of Revenue | 38.84M | 46.25M | 45.73M | 35.38M | 42.32M |
| Gross Profit | -37.54M | -43.35M | -40.82M | -28.28M | -32.75M |
| SG&A Expenses | 13.55M | 13.98M | 14.64M | 14.28M | 14.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.97M | 60.92M | 61.06M | 50.34M | 57.06M |
| Operating Income | -50.67M | -58.01M | -56.15M | -43.24M | -47.49M |
| Income Before Tax | -48.34M | -55.45M | -53.04M | -39.43M | -43.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.34 | -55.45 | -53.04 | -39.43 | -43.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.34M | -55.45M | -53.04M | -39.43M | -43.11M |
| EBIT | -50.67M | -58.01M | -56.15M | -43.24M | -47.49M |
| EBITDA | -50.63M | -57.97M | -56.11M | -43.19M | -47.43M |
| EPS Basic | -85.79 | -99.02 | -96.27 | -71.99 | -79.00 |
| Normalized Basic EPS | -53.62 | -61.89 | -60.17 | -44.99 | -49.38 |
| EPS Diluted | -85.79 | -99.02 | -96.27 | -71.99 | -79.00 |
| Normalized Diluted EPS | -53.62 | -61.89 | -60.17 | -44.99 | -49.38 |
| Average Basic Shares Outstanding | 2.28M | 2.24M | 2.20M | 2.19M | 2.18M |
| Average Diluted Shares Outstanding | 2.28M | 2.24M | 2.20M | 2.19M | 2.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |